Exchange: NASDAQ·Updated 07:30 PM EST

GRAL News

News
all
press releases
GRAIL, Inc. (NASDAQ:GRAL) Stock Rated "Hold" by Wall Street Analysts
GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) has earned a consensus rating of "Hold" from the twelve research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and five have given a...
MarketBeat
GRAIL, Inc. (NASDAQ:GRAL) Stock Rated "Hold" by Wall Street Analysts
GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) has earned a consensus rating of "Hold" from the twelve research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and five have given a...
MarketBeat
More News
Emerging Technologies Target Earlier Detection of Breast and Colon Cancer as Global Demand for Advanced Diagnostics Accelerates   New York, NY – November 20, 2026 – A simple blood test that can detect cancer before symptoms appear is one of the most compelling developments taking shape in modern medicine. Biotechnology companies are now using artificial […] The post AI-Powered Cancer Blood Tests Set the Stage for a Multibillion-Dollar Biotech Breakthrough appeared first on Financial News Media.
Financial News Media
GRAIL (NASDAQ:GRAL) Shares Up 6% - Here's Why...
MarketBeat
GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) CFO Aaron Freidin sold 3,000 shares of the company's stock in a transaction on Monday, November 16th. The stock was sold at an average price of $107.62, for a total value of $322,860.00. Following the completion of the sale, the chief financial officer...
MarketBeat
GRAL is cutting Galleri prices to boost adoption ahead of an expected early 2027 FDA decision, even as pricing pressure weighs on revenue growth and margins.
Zacks
GRAIL Reports Third Quarter 2026 Financial Results GRAIL Reports Third Quarter 2026 Financial ResultsPR NewswireSUNNYVALE, Calif., Nov. 4, 2026 FDA Advisory Committee Voted in Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection TestQ3 GalleriTest Volume Increased ~24% to More Than...
PR Newswire
GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
Zacks
GRAIL to Present at the UBS Global Healthcare Conference GRAIL to Present at the UBS Global Healthcare ConferencePR NewswireSUNNYVALE, Calif., Oct. 27, 2026 SUNNYVALE, Calif., Oct. 27, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when...
PR Newswire
GRAIL to Announce Third Quarter 2026 Financial Results GRAIL to Announce Third Quarter 2026 Financial ResultsPR NewswireSUNNYVALE, Calif., Oct. 21, 2026 SUNNYVALE, Calif., Oct. 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it...
PR Newswire
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026 GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026PR NewswireSUNNYVALE, Calif., Oct. 5, 2026GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference...
PR Newswire

Advertisement|Remove ads.